Publications

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J and Palmer JP: A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History. Diabetes Care. 2014 Dec 17; Epub 2014 Dec 17. PMID: 25519451


Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC and Ledizet M: Analysis of β-cell death in type 1 diabetes by droplet digital PCR. Endocrinology. 2014 Sep;155 (9) :3694-8. Epub 2014 Jul 8. PMID: 25004096


Tooley JE and Herold KC: Biomarkers in type 1 diabetes: application to the clinical trial setting. Curr Opin Endocrinol Diabetes Obes. 2014 Aug;21 (4) :287-92. PMID: 24937037


Vudattu NK, Waldron-Lynch F, Truman LA, Deng S, Preston-Hurlburt P, Torres R, Raycroft MT, Mamula MJ and Herold KC: Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol. 2014 Jul 15;193 (2) :587-96. Epub 2014 Jun 18. PMID: 24943216


Viehmann Milam AA, Maher SE, Gibson JA, Lebastchi J, Wen L, Ruddle NH, Herold KC and Bothwell AL: A humanized mouse model of autoimmune insulitis. Diabetes. 2014 May;63 (5) :1712-24. Epub 2014 Jan 29. PMID: 24478396


Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G and Palmer JP: Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care. 2014 Apr;37 (4) :979-84. Epub 2014 Feb 18. PMID: 24550217


Vudattu NK and Herold KC: Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development. Expert Opin Biol Ther. 2014 Mar;14 (3) :377-85. PMID: 24517093


Sherr JL, Ghazi T, Wurtz A, Rink L and Herold KC: Characterization of residual β cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev. 2014 Feb;30 (2) :154-62. PMID: 24115337


Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, Hija A, Stolovich-Rain M, Furth-Lavi J, Granot Z, Porat S, Philipson LH, Herold KC, Bhatti TR, Stanley C, Ashcroft FM, In't Veld P, Saada A, Magnuson MA, Glaser B and Dor Y: Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in β cells. Cell Metab. 2014 Jan 7;19 (1) :109-21. Epub 2013 Dec 12. PMID: 24332968


Ghazi T, Rink L, Sherr JL and Herold KC: Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care. 2014 Jan;37 (1) :210-6. Epub 2013 Aug 12. PMID: 23939544


Akirav EM, Henegariu O, Preston-Hurlburt P, Schmidt AM, Clynes R and Herold KC: The receptor for advanced glycation end products (RAGE) affects T cell differentiation in OVA induced asthma. PLoS One. 2014;9 (4) :e95678. Epub 2014 Apr 23. PMID: 24759895

Daifotis AG, Koenig S, Chatenoud L and Herold KC: Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol. 2013 Dec;149 (3) :268-78. Epub 2013 May 11. PMID: 23726024


Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC and Palmer JP: Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes. 2013 Dec;62 (12) :4179-83. Epub 2013 Jul 17. PMID: 23863814


Herold KC: Restoring immune balance in type 1 diabetes. Lancet Diabetes Endocrinol. 2013 Dec;1 (4) :261-3. Epub 2013 Sep 23. PMID: 24622404


Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J and Bluestone JA: Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62 (11) :3766-74. Epub 2013 Jul 8. PMID: 23835333


Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC and Ludvigsson J: Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013 Nov;62 (11) :3901-8. Epub 2013 Jun 25. PMID: 23801579


Vudattu NK and Herold KC: Delayed anti-CD3 therapy in a mouse heart transplant model induced tolerance and long-term survival of allograft: achieving tolerance. Immunotherapy. 2013 Nov;5 (11) :1173-6. PMID: 24188671


Kinnunen T, Chamberlain N, Morbach H, Cantaert T, Lynch M, Preston-Hurlburt P, Herold KC, Hafler DA, O'Connor KC and Meffre E: Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013 Jun 3;123 (6) :2737-41. Epub 2013 May 15. PMID: 23676463


Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H and Mandrup-Poulsen T: Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013 Jun 1;381 (9881) :1905-15. Epub 2013 Apr 5. PMID: 23562090


Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA and Herold KC: Immune therapy and β-cell death in type 1 diabetes. Diabetes. 2013 May;62 (5) :1676-80. Epub 2013 Feb 19. PMID: 23423576


Herold KC, Vignali DA, Cooke A and Bluestone JA: Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol. 2013 Apr;13 (4) :243-56. PMID: 23524461


Hughes JW and Herold KC: Novel SIRT1 mutation linked to autoimmune diabetes in humans. Cell Metab. 2013 Mar 5;17 (3) :311-2. PMID: 23473025


Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J and Bluestone JA: Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013 Feb;56 (2) :391-400. Epub 2012 Oct 21. PMID: 23086558

Waldron-Lynch F, Inzucchi SE, Menard L, Tai N, Preston-Hurlburt P, Hui P, McClaskey J, Hagopian WA, Meffre E, Marks PW, Wen L and Herold KC: Relapsing and remitting severe hypoglycemia due to a monoclonal anti-insulin antibody heralding a case of multiple myeloma. J Clin Endocrinol Metab. 2012 Dec;97 (12) :4317-23. Epub 2012 Oct 16. PMID: 23074233


Waldron-Lynch F, Deng S, Preston-Hurlburt P, Henegariu O and Herold KC: Analysis of human biologics with a mouse skin transplant model in humanized mice. Am J Transplant. 2012 Oct;12 (10) :2652-62. Epub 2012 Aug 17. PMID: 22900715


Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS and Sosenko JM: Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 2012 Aug;61 (8) :2066-73. Epub 2012 Jun 11. PMID: 22688329


Lebastchi J and Herold KC: Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes. Cold Spring Harb Perspect Med. 2012 Jun;2 (6) :a007708. PMID: 22675665


Sosenko JM, Skyler JS, Herold KC and Palmer JP: The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes. 2012 Jun;61 (6) :1331-7. PMID: 22618768


Normandin MD, Petersen KF, Ding YS, Lin SF, Naik S, Fowles K, Skovronsky DM, Herold KC, McCarthy TJ, Calle RA, Carson RE, Treadway JL and Cline GW: In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med. 2012 Jun;53 (6) :908-16. Epub 2012 May 9. PMID: 22573821


Tooley JE, Waldron-Lynch F and Herold KC: New and future immunomodulatory therapy in type 1 diabetes. Trends Mol Med. 2012 Mar;18 (3) :173-81. Epub 2012 Feb 17. PMID: 22342807


Waldron-Lynch F, Henegariu O, Deng S, Preston-Hurlburt P, Tooley J, Flavell R and Herold KC: Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med. 2012 Jan 25;4 (118) :118ra12. PMID: 22277969


Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, Santamaria P, Mandrup-Poulsen T and Herold KC: Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes. 2012 Jan;61 (1) :145-54. Epub 2011 Oct 31. PMID: 22043003


Ablamunits V, Klebanov S, Giese SY and Herold KC: Functional human to mouse adipose tissue xenotransplantation. J Endocrinol. 2012 Jan;212 (1) :41-7. Epub 2011 Oct 17. PMID: 22007021


Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, Schmidt AM and Herold KC: RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS One. 2012;7 (4) :e34698. Epub 2012 Apr 11. PMID: 22509345

Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS and Weinberg A: Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol. 2011 Dec;128 (6) :1295-1302.e5. Epub 2011 Sep 9. PMID: 21908031


Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V, Lizardi PM and Herold KC: Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A. 2011 Nov 22;108 (47) :19018-23. Epub 2011 Nov 9. PMID: 22074781


Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K, Asare A, Liu Z, Lachin JM and Dosch HM: Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol. 2011 Aug 15;187 (4) :1998-2005. Epub 2011 Jul 20. PMID: 21775681


Herold KC and Bluestone JA: Type 1 diabetes immunotherapy: is the glass half empty or half full? Sci Transl Med. 2011 Aug 10;3 (95) :95fs1. PMID: 21832236


Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC and Daifotis AG: Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet. 2011 Aug 6;378 (9790) :487-97. Epub 2011 Jun 28. PMID: 21719095


Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP and Skyler JS: Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011 Jul 23;378 (9788) :319-27. Epub 2011 Jun 27. PMID: 21714999


Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O'Connor W Jr, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC and Flavell RA: Control of TH17 cells occurs in the small intestine. Nature. 2011 Jul 17;475 (7357) :514-8. Epub 2011 Jul 17. PMID: 21765430


Ablamunits V, Henegariu O, Preston-Hurlburt P and Herold KC: NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody. Eur J Immunol. 2011 Jul;41 (7) :1832-42. Epub 2011 Jun 6. PMID: 21538351


Waldron-Lynch F and Herold KC: Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat Rev Drug Discov. 2011 Jun;10 (6) :439-52. PMID: 21629294


Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, Pietropaolo M, Arvan PR, Von Herrath M, Markel DS and Rhodes CJ: How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes. 2011 May;60 (5) :1370-9. PMID: 21525508


Akirav EM, Baquero MT, Opare-Addo LW, Akirav M, Galvan E, Kushner JA, Rimm DL and Herold KC: Glucose and inflammation control islet vascular density and beta-cell function in NOD mice: control of islet vasculature and vascular endothelial growth factor by glucose. Diabetes. 2011 Mar;60 (3) :876-83. Epub 2011 Feb 9. PMID: 21307078


Kochar R and Herold KC: Prevention of T1DM: feeding the ultimate goal. Nat Rev Endocrinol. 2011 Mar;7 (3) :132-4. Epub 2011 Feb 8. PMID: 21301485


Akirav EM, Ruddle NH and Herold KC: The role of AIRE in human autoimmune disease. Nat Rev Endocrinol. 2011 Jan;7 (1) :25-33. Epub 2010 Nov 23. PMID: 21102544

Ablamunits V, Bisikirska B and Herold KC: Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40 (10) :2891-901. PMID: 21038470


Luo X, Herold KC and Miller SD: Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity. 2010 Apr 23;32 (4) :488-99. PMID: 20412759


Cernea S and Herold KC: Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin Immunol. 2010 Feb;134 (2) :121-9. PMID: 19837003

Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C and Lachin JM: Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes. 2009 Nov;58 (11) :2588-95. Epub 2009 Aug 12. PMID: 19675135


Cernea S, Raz I, Herold KC, Hirshberg B, Roep BO, Schatz DA, Fleming GA, Pozzilli P, Little R, Schloot NC, Leslie RD, Skyler JS and Palmer JP: Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev. 2009 Nov;25 (8) :694-704. PMID: 19771545


Begum S, Chen W, Herold KC and Papaioannou VE: Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors. Endocrinology. 2009 Oct;150 (10) :4512-20. Epub 2009 Jul 9. PMID: 19589867


Lepus CM, Gibson TF, Gerber SA, Kawikova I, Szczepanik M, Hossain J, Ablamunits V, Kirkiles-Smith N, Herold KC, Donis RO, Bothwell AL, Pober JS and Harding MJ: Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum Immunol. 2009 Oct;70 (10) :790-802. Epub 2009 Jun 12. PMID: 19524633


Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K and Bluestone JA: Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug;132 (2) :166-73. Epub 2009 May 14. PMID: 19443276


Waldron-Lynch F and Herold KC: Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage. Endocrinol Metab Clin North Am. 2009 Jun;38 (2) :303-17, viii. PMID: 19328413


Kaufman A and Herold KC: Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev. 2009 May;25 (4) :302-6. PMID: 19319985


Chen W, Begum S, Opare-Addo L, Garyu J, Gibson TF, Bothwell AL, Papaioannou VE and Herold KC: Promotion of beta-cell differentiation in pancreatic precursor cells by adult islet cells. Endocrinology. 2009 Feb;150 (2) :570-9. Epub 2008 Oct 9. PMID: 18845629


Waldron-Lynch F and Herold KC: Continuous glucose monitoring: long live the revolution! Nat Clin Pract Endocrinol Metab. 2009 Feb;5 (2) :82-3. Epub 2008 Dec 17. PMID: 19092785

Ablamunits V, Bisikirska BC and Herold KC: Human regulatory CD8 T cells. Ann N Y Acad Sci. 2008 Dec;1150 :234-8. PMID: 19120302


Akirav E, Kushner JA and Herold KC: Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes. 2008 Nov;57 (11) :2883-8. PMID: 18971435


Ablamunits V and Herold KC: Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala). Hum Immunol. 2008 Nov;69 (11) :732-6. Epub 2008 Sep 24. PMID: 18817833


Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R and Herold KC: RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181 (6) :4272-8. PMID: 18768885


Sherr J, Sosenko J, Skyler JS and Herold KC: Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab. 2008 Jun;4 (6) :334-43. Epub 2008 Apr 29. PMID: 18446141


King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, Atkinson MA, Wasserfall C, Herold KC, Woodland RT, Schmidt MR, Woda BA, Thompson MJ, Rossini AA and Greiner DL: A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol. 2008 Mar;126 (3) :303-14. Epub 2007 Dec 21. PMID: 18096436


Waldron-Lynch F, von Herrath M and Herold KC: Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass. Novartis Found Symp. 2008;292 :146-55; discussion 155-8, 202-3. PMID: 19203097

Page KA, Dejardin S, Kahn CR, Kulkarni RN, Herold KC and Inzucchi SE: A patient with type B insulin resistance syndrome, responsive to immune therapy. Nat Clin Pract Endocrinol Metab. 2007 Dec;3 (12) :835-40. PMID: 18026162


Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM and Herold KC: Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology. 2007 Nov;148 (11) :5136-44. Epub 2007 Aug 2. PMID: 17673522


Ablamunits V, Sherry NA, Kushner JA and Herold KC: Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough. Ann N Y Acad Sci. 2007 Apr;1103 :19-32. Epub 2007 Mar 21. PMID: 17376841


Moser B, Szabolcs MJ, Ankersmit HJ, Lu Y, Qu W, Weinberg A, Herold KC and Schmidt AM: Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation. Am J Transplant. 2007 Feb;7 (2) :293-302. PMID: 17241110


Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D and Skyler JS: Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care. 2007 Jan;30 (1) :38-42. PMID: 17192330


Witkowski P and Herold KC: Islet transplantation for type 1 diabetes--where should we go? Nat Clin Pract Endocrinol Metab. 2007 Jan;3 (1) :2-3. PMID: 17179921

Sherry NA, Kushner JA, Glandt M, Kitamura T, Brillantes AM and Herold KC: Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes. 2006 Dec;55 (12) :3238-45. PMID: 17130466


Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA and Herold KC: Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006 Sep;55 (9) :2588-94. PMID: 16936208


Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC and von Herrath M: Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest. 2006 May;116 (5) :1371-81. Epub 2006 Apr 20. PMID: 16628253


Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D and Skyler JS: Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2006 Mar;29 (3) :643-9. PMID: 16505520


Tsai EB, Sherry NA, Palmer JP and Herold KC: The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006 Feb;49 (2) :261-70. Epub 2006 Jan 11. PMID: 16404554


Cernea S and Herold KC: Drug insight: New immunomodulatory therapies in type 1 diabetes. Nat Clin Pract Endocrinol Metab. 2006 Feb;2 (2) :89-98. PMID: 16932263


Moser B, Herold KC and Schmidt AM: Receptor for advanced glycation end products and its ligands: initiators or amplifiers of joint inflammation--a bit of both? Arthritis Rheum. 2006 Jan;54 (1) :14-8. PMID: 16385492

Sherry NA, Tsai EB and Herold KC: Natural history of beta-cell function in type 1 diabetes. Diabetes. 2005 Dec;54 Suppl 2 :S32-9. PMID: 16306337


Bisikirska B, Colgan J, Luban J, Bluestone JA and Herold KC: TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct;115 (10) :2904-13. Epub 2005 Sep 15. PMID: 16167085


Chen W, Bluestone JA and Herold KC: Achieving antigen-specific tolerance in diabetes: regulating specifically. Int Rev Immunol. 2005 Sep-Dec;24 (5-6) :287-305. PMID: 16318983


Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM and Bluestone JA: A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun;54 (6) :1763-9. PMID: 15919798


Bisikirska BC and Herold KC: Regulatory T cells and type 1 diabetes. Curr Diab Rep. 2005 Apr;5 (2) :104-9. PMID: 15794912


Rong LL, Gooch C, Szabolcs M, Herold KC, Lalla E, Hays AP, Yan SF, Yan SS and Schmidt AM: RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor Neurol Neurosci. 2005;23 (5-6) :355-65. PMID: 16477098

Bisikirska BC and Herold KC: Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes. Ann N Y Acad Sci. 2004 Dec;1037 :1-9. PMID: 15699486


Siegel-Czarkowski L, Herold KC and Goland RS: Continuous subcutaneous insulin infusion in older patients with type 1 diabetes. Diabetes Care. 2004 Dec;27 (12) :3022-3. PMID: 15562235


Glandt M and Herold KC: Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation. Curr Diab Rep. 2004 Aug;4 (4) :291-7. PMID: 15265472


Chen Y, Yan SS, Colgan J, Zhang HP, Luban J, Schmidt AM, Stern D and Herold KC: Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol. 2004 Jul 15;173 (2) :1399-405. PMID: 15240736


Herold KC: Treatment of type 1 diabetes mellitus to preserve insulin secretion. Endocrinol Metab Clin North Am. 2004 Mar;33 (1) :93-111, ix. PMID: 15053897


Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J and Herold KC: Insulin secretion in type 1 diabetes. Diabetes. 2004 Feb;53 (2) :426-33. PMID: 14747294


Herold KC: Achieving antigen-specific immune regulation. J Clin Invest. 2004 Feb;113 (3) :346-9. PMID: 14755329


Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS and Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 2004 Jan;53 (1) :250-64. PMID: 14693724

Glandt M, Hagopian W and Herold KC: Treatment of type 1 diabetes with anti-CD3 monoclonal antibody. Rev Endocr Metab Disord. 2003 Dec;4 (4) :361-8. PMID: 14618021


Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M and Bluestone JA: Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest. 2003 Feb;111 (3) :409-18. PMID: 12569167


Herold KC and Taylor L: Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation? Immunol Res. 2003;28 (2) :141-50. PMID: 14610290

Fontaine MJ, Blanchard J, Rastellini C, Lazda V, Herold KC and Pollak R: Pancreatic islets activate portal vein endothelial cells in vitro. Ann Clin Lab Sci. 2002 Fall;32 (4) :352-61. PMID: 12458886


Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA and Bluestone JA: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30;346 (22) :1692-8. PMID: 12037148

Herold KC: Hepatitis C virus infection. N Engl J Med. 2001 Nov 8;345 (19) :1426; author reply 1427-8. PMID: 11794187

Liu EH and Herold KC: Transplantation of the islets of Langerhans: new hope for treatment of type 1 diabetes mellitus. Trends Endocrinol Metab. 2000 Nov;11 (9) :379-82. PMID: 11042469


Artwohl JE, Flynn JC, Bunte RM, Angen O and Herold KC: Outbreak of Pasteurella pneumotropica in a closed colony of STOCK-Cd28(tm1Mak) mice. Contemp Top Lab Anim Sci. 2000 Jan;39 (1) :39-41. PMID: 11178314

Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM and Herold KC: Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med. 1998 Jan 22;338 (4) :226-30. PMID: 9435328

Herold KC, Lu J, Rulifson I, Vezys V, Taub D, Grusby MJ and Bluestone JA: Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. J Immunol. 1997 Nov 1;159 (9) :4150-3. PMID: 9379007


Herold KC, Baumann E, Vezys V and Buckingham F: Expression and immune response to islet antigens following treatment with low doses of streptozotocin in H-2d mice. J Autoimmun. 1997 Feb;10 (1) :17-25. PMID: 9080296


Herold KC, Vezys V, Koons A, Lenschow D, Thompson C and Bluestone JA: CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol. 1997 Jan 15;158 (2) :984-91. PMID: 8993020

Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB and Bluestone JA: CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity. 1996 Sep;5 (3) :285-93. PMID: 8808683


Herold KC, Vezys V, Sun Q, Viktora D, Seung E, Reiner S and Brown DR: Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol. 1996 May 1;156 (9) :3521-7. PMID: 8617981

Baumann EE, Buckingham F and Herold KC: Intrathymic transplantation of islet antigen affects CD8+ diabetogenic T-cells resulting in tolerance to autoimmune IDDM. Diabetes. 1995 Aug;44 (8) :871-7. PMID: 7621990


O'Meara NM, Sturis J, Herold KC, Ostrega DM and Polonsky KS: Alterations in the patterns of insulin secretion before and after diagnosis of IDDM. Diabetes Care. 1995 Apr;18 (4) :568-71. PMID: 7497873


Herold KC, Bloch TN, Vezys V and Sun Q: Diabetes induced with low doses of streptozotocin is mediated by V beta 8.2+ T-cells. Diabetes. 1995 Mar;44 (3) :354-9. PMID: 7883124


Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC and Bluestone JA: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med. 1995 Mar 1;181 (3) :1145-55. PMID: 7532678

Herold KC, Vezys V, Gage A and Montag AG: Prevention of autoimmune diabetes by treatment with anti-LFA-1 and anti-ICAM-1 monoclonal antibodies. Cell Immunol. 1994 Sep;157 (2) :489-500. PMID: 7915204


Alegre ML, Sattar HA, Herold KC, Smith J, Tepper MA and Bluestone JA: Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation. 1994 Jun 27;57 (12) :1786-94. PMID: 8016885

Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P and Steiner DF: Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation. 1993 Jan;55 (1) :186-92. PMID: 7678356

Nossal GJ, Herold KC and Goodnow CC: Autoimmune tolerance and type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1992 Dec;35 Suppl 2 :S49-59. PMID: 1478378


Herold KC, Montag AG and Buckingham F: Induction of tolerance to autoimmune diabetes with islet antigens. J Exp Med. 1992 Oct 1;176 (4) :1107-14. PMID: 1402656


Herold KC and Rubenstein AH: New directions in the immunology of autoimmune diabetes. Ann Intern Med. 1992 Sep 1;117 (5) :436-8. PMID: 1503336


Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE and Hirsch R: Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes. 1992 Mar;41 (3) :385-91. PMID: 1532369

Herold KC and Polonsky KS: Does tight glucose control enhance brain sensitivity to low glucose? Diabetes Care. 1991 Feb;14 (2) :141-3. PMID: 2060418

Herold KC, Montag AG, Meyer SM, Wojcikowski C and Fitch FW: Expression of Ly-6C by T lymphocytes of NOD mice after CD3-complex stimulation. Identification of activated cells during insulitis of prediabetic mice. Diabetes. 1990 Jul;39 (7) :815-20. PMID: 2162302

Loeb JA, Herold KC, Barton KP, Robinson LE and Jaspan JB: Systematic approach to diagnosis and management of biphasic insulin allergy with local anti-inflammatory agents. Diabetes Care. 1989 Jun;12 (6) :421-3. PMID: 2659301


Herold KC, Kastern W, Markholst H and Lernmark A: Derivation of non-lymphopenic BB rats with an intercross breeding. Autoimmunity. 1989;3 (2) :83-93. PMID: 2577492

Herold KC and Rubenstein AH: Immunosuppression for insulin-dependent diabetes. N Engl J Med. 1988 Mar 17;318 (11) :701-3. PMID: 3344022

Dunn DE, Herold KC, Otten GR, Lancki DW, Gajewski T, Vogel SN and Fitch FW: Interleukin 2 and concanavalin A stimulate interferon-gamma production in a murine cytolytic T cell clone by different pathways. J Immunol. 1987 Dec 15;139 (12) :3942-8. PMID: 3121725


Otten G, Herold KC and Fitch FW: Interleukin 2 inhibits antigen-stimulated lymphokine synthesis in helper T cells by inhibiting calcium-dependent signalling. J Immunol. 1987 Aug 15;139 (4) :1348-53. PMID: 2956328


Herold KC, Montag AG and Fitch FW: Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozocin. Diabetes. 1987 Jul;36 (7) :796-801. PMID: 3556279

Herold KC, Lancki DW, Dunn DE, Arai K and Fitch FW: Activation of lymphokine genes during stimulation of cloned T cells. Eur J Immunol. 1986 Dec;16 (12) :1533-8. PMID: 3102245


Herold KC and Jaspan JB: Hepatic glucagon clearance during insulin induced hypoglycemia. Horm Metab Res. 1986 Jul;18 (7) :431-5. PMID: 3527924


Moldwin RL, Lancki DW, Herold KC and Fitch FW: An antigen receptor-driven, interleukin 2-independent pathway for proliferation of murine cytolytic T lymphocyte clones. J Exp Med. 1986 Jun 1;163 (6) :1566-82. PMID: 3486939


Herold KC, Lancki DW, Moldwin RL and Fitch FW: Immunosuppressive effects of cyclosporin A on cloned T cells. J Immunol. 1986 Feb 15;136 (4) :1315-21. PMID: 2935576

Herold KC, Polonsky KS, Cohen RM, Levy J and Douglas F: Variable deterioration in cortical function during insulin-induced hypoglycemia. Diabetes. 1985 Jul;34 (7) :677-85. PMID: 3891475

Polonsky KS, Herold KC, Gilden JL, Bergenstal RM, Fang VS, Moossa AR and Jaspan JB: Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes. Diabetes. 1984 Nov;33 (11) :1112-9. PMID: 6389228


Herold KC, Huen A, Gould L, Traisman H and Rubenstein AH: Alterations in lymphocyte subpopulations in type 1 (insulin-dependent) diabetes mellitus: exploration of possible mechanisms and relationships to autoimmune phenomena. Diabetologia. 1984 Jul;27 Suppl :102-5. PMID: 6237011